Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00060449" target="_blank" >RIV/00216224:14110/12:00060449 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/12:43896924 RIV/65269705:_____/12:#0001912 RIV/00064173:_____/12:43896924
Výsledek na webu
<a href="http://dx.doi.org/10.1016/S0140-6736(11)61940-5" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(11)61940-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0140-6736(11)61940-5" target="_blank" >10.1016/S0140-6736(11)61940-5</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Popis výsledku v původním jazyce
Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective randomised clinical trial comparing two reduced-intensity chemotherapy variants with our previous standard regimen. Chemotherapy was followed by PET-guided radiotherapy. Methods In this parallel group, open-label, multicentre, non-inferiority trial (HD15), 2182 patients with newly diagnosed advanced stage Hodgkin's lymphoma aged 18-60 years were randomly assigned to receive either eight cycles of BEACOPP(escalated) (8xB(esc) group), six cycles of BEACOPP(escalated) (6xB(esc) group), or eight cycles of BEACOPP(14) (8xB(14) group). Randomisation (1:1:1) was done centrally by stratified minimisation. Non-inferiority of the primary endpoint, freedom from treatment failure, was assessed using repeated CIs for the hazard ratio (HR) according to the intention-to-treat principle. Patients with a persistent mass after chemotherap
Název v anglickém jazyce
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Popis výsledku anglicky
Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We did a prospective randomised clinical trial comparing two reduced-intensity chemotherapy variants with our previous standard regimen. Chemotherapy was followed by PET-guided radiotherapy. Methods In this parallel group, open-label, multicentre, non-inferiority trial (HD15), 2182 patients with newly diagnosed advanced stage Hodgkin's lymphoma aged 18-60 years were randomly assigned to receive either eight cycles of BEACOPP(escalated) (8xB(esc) group), six cycles of BEACOPP(escalated) (6xB(esc) group), or eight cycles of BEACOPP(14) (8xB(14) group). Randomisation (1:1:1) was done centrally by stratified minimisation. Non-inferiority of the primary endpoint, freedom from treatment failure, was assessed using repeated CIs for the hazard ratio (HR) according to the intention-to-treat principle. Patients with a persistent mass after chemotherap
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Lancet
ISSN
0140-6736
e-ISSN
—
Svazek periodika
379
Číslo periodika v rámci svazku
9828
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
9
Strana od-do
1791-1799
Kód UT WoS článku
000303937700033
EID výsledku v databázi Scopus
—